Company Filing History:
2 out of 7 
1 out of 13 Years Active: 2011-2016
Title: Nabila Seddiki: Innovator in Regulatory T Cell Research
Introduction
Nabila Seddiki is a prominent inventor based in Newtown, Australia. She has made significant contributions to the field of immunology, particularly in the identification and application of regulatory T cells. With a total of three patents to her name, her work is pivotal in advancing medical diagnostics and therapies.
Latest Patents
Nabila Seddiki's latest patents include a "Kit for identifying regulatory T cells." This invention relates to methods and kits for identifying, quantifying, and isolating regulatory T cells. It also encompasses methods for diagnosing or monitoring autoimmune diseases, immunoinflammatory diseases, allergic diseases, predispositions to these conditions, infectious diseases, cancer, and organ transplantation based on regulatory T cell quantity. Additionally, it provides methods for predicting responses to therapy and for therapy using isolated regulatory T cells. Another notable patent is the "Method for identifying antigen-specific regulatory T cells." This method involves detecting co-expression of specific cell markers in response to exposure to a target antigen, which may facilitate antigen-specific Treg cell therapy.
Career Highlights
Throughout her career, Nabila has worked with esteemed organizations such as the Centenary Institute of Cancer Medicine and Cell Biology and St. Vincent's Hospital Sydney Limited. Her research has been instrumental in enhancing the understanding of regulatory T cells and their therapeutic potential.
Collaborations
Nabila has collaborated with notable professionals in her field, including Anthony Dominic Kelleher and John James Zaunders. These collaborations have further enriched her research and contributed to the advancement of immunological studies.
Conclusion
Nabila Seddiki's innovative work in regulatory T cell research has the potential to transform the landscape of medical diagnostics and therapies. Her contributions are vital for the future of immunology and patient care.